Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie — Clinical Trial Site

70 Registered trials

35 Currently recruiting

Organisation

Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie

Location

Olsztyn, Poland

Identifier

ORG-100045165

Address

Ul. Jagiellonska Nr 78, 10-357, Poland

Departments

#5705 Oddzial Onkologii z Pododdzialem Chemioterapii
5701: Oddzial Onkologii z Pododdzialem Chemioterapii
5705: Oddział Onkologii z Pododdziałem Chemioterapii
Klinika Pulmonologii
N/A
NA
NA Oddział Onkologii z Pododdziałem Chemioterapii
Oddzal Onkologii z Pododdzialem Chemioterapii
Oddzial onkologii z pododdziałem chemioterapii
Oddzial onkologii z poddodzialem chemioterapii
Oddzial Onkologii z Pododdzialem Chemioterapii
Oddzial Onkologii z Pododdziałem Chemioterapii
Oddzial Onkologii z Pododzialem Chemioterapii
Oddział Alergologiczno-Pulmonologiczny
Oddział Onkologii
Oddział Onkologii i pododdziałem chemioterapii
Oddział Onkologii z Pododdziałem Chemioterapii
Oddział Onkologii z Pododdziałem Chemioterapii
Oddział Onkologii z PododdziałemChemioterapii
Oddział Onkologii z Pododziałem Chemioterapii
Oddziatu Onkologii z Pododdziatem Chemioterapi
Oncology
Oncology Department with Chemotherapy Sub-Division

Clinical trials at this site (70)

Search interface

A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended

2023-507687-38-00 Participants with extensive-stage small cell lung cance 9 2021-08-23
A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended

2023-508372-10-00 Non small Cell Lung cancer 4 2021-05-19
A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact… Ended

2022-502606-33-00 Patients with histologically or cytologically documente 5 2021-02-26
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC… Ended

2023-507475-21-00 Lung Cancer, Non-Small Cell 10 2021-01-18
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended

2023-506576-27-00 EGFR-mutated locally advanced or metastatic Non Small C 5 2020-09-30
A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended

2023-509576-42-00 Patients with resectable Non-small Cell Lung Cancer (St 5 2019-02-21
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 5 2019-02-11
A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re… Ended

2023-506861-76-00 Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage 5 2018-08-09
A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small C… Ended

2023-507500-31-00 Advanced or metastatic Non-small cell lung cancer (NSCL 10 2017-08-22
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced l… Ended

2023-509644-10-00 Advanced Non-small Cell Lung Cancer 9 2024-06-27
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release… Ended

2023-505296-72-00 Idiopathic Pulmonary Fibrosis (IPF) 4 2023-12-12
Phase 2 First-Line ES-SCLC Platform Study Ended

2023-506538-56-00 First-line treatment of participants with extensive-sta 4 2021-08-12
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18
A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C… Ended

2022-502031-20-00 Non-squamous non-small cell lung cancer (NSCLC) 10 2020-12-17
TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended

2023-505894-33-00 Lung Cancer, Non-Small Cell 4 2020-11-25
A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensiv… Ended

2022-502988-37-00 Small cell lung cancer (SCLC) 5 2020-06-19
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 5 2019-06-26
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 Stage IV lung cancer condition 5 2019-06-25
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Ended

2024-515051-38-00 Non-small Cell Lung Cancer 5 2018-07-20
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Parti… Ended

2023-506859-13-00 Anaplastic lymphoma kinase (ALK)-positive non-small cel 5 2014-09-09